Laura Vegar
0009-0002-9860-746X
Mirati Therapeutics (United States)
2 papers found
Refreshing results…
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
Missing publications? Search for publications with a matching author name.